OpenNashEarnings

Takeda (TAK) · Pharmaceuticals

Takeda Q2 FY2026 earnings: summary, key numbers & outlook

Results filed 29 Oct 2026 · Quarter ended 30 Sep 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Takeda's growth leaned on subcutaneous ENTYVIO and immunoglobulin demand, while new launches grew 17.3% at constant exchange rates but remain a small share of the business.

Demand centered on gastroenterology and plasma-derived therapies. ENTYVIO grew with the subcutaneous formulation in the U.S. and Europe, and subcutaneous immunoglobulins CUVITRU and HYQVIA grew at double-digit rates. Newer products added momentum: LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA each grew on launch or expanded-use gains. TRINTELLIX benefited from U.S. pricing and payer mix. Takeda also discontinued its cell therapy research.

Management is pushing late-stage pipeline programs, including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928, while a transformation program continues with restructuring costs. The main tension is that established brands were broadly flat and products losing exclusivity declined. New launches are only 4% of core revenue, so they must scale to replace what is fading.

Key numbers

Revenue (six months ended Sept 30, 2026) · GAAP
JPY 2,407.0 billion

up 8.4% at actual exchange rates, down 1.0% at constant exchange rates from a year ago

Operating profit (six months) · GAAP
JPY 406.7 billion

up 60.4% at actual exchange rates, up 45.0% at constant exchange rates

Net profit attributable to owners (six months) · GAAP
JPY 305.6 billion

up 171.8% at actual exchange rates, up 148.9% at constant exchange rates

Diluted EPS (JPY, six months) · GAAP
189.52

up from 70.45 a year ago

Core EPS (six months) · non-GAAP
JPY 308

up 10.5% at actual exchange rates, down 1.2% at constant exchange rates

Net cash from operating activities (six months) · GAAP
JPY 431.9 billion

down JPY 161.8 billion from a year ago

Core operating profit (six months) · non-GAAP
JPY 710.6 billion

up 11.2% at actual exchange rates, up 0.7% at constant exchange rates

Segment or metricValueChange
Gastroenterology (GI)JPY 776.8 billionup 12.1% at actual exchange rates, up 2.5% at constant exchange rates
Rare DiseasesJPY 395.7 billionup 4.0% at actual exchange rates, down 5.6% at constant exchange rates
Plasma-Derived Therapies (PDT)JPY 561.2 billionup 8.5% at actual exchange rates, down 1.5% at constant exchange rates
OncologyJPY 317.0 billionup 10.1% at actual exchange rates, up 0.9% at constant exchange rates
VaccinesJPY 36.6 billionup 15.7% at actual exchange rates, up 7.7% at constant exchange rates
NeuroscienceJPY 220.9 billionup 7.2% at actual exchange rates, down 1.6% at constant exchange rates
ENTYVIOJPY 541.7 billionup 13.0% at actual exchange rates, up 2.7% at constant exchange rates
Where each number comes from
  • Revenue (six months ended Sept 30, 2026): “Revenue for the six-month period ended September 30, 2026 was JPY 2,407.0 billion (JPY +187.5 billion and +8.4% AER, -1.0% CER).”
  • Operating profit (six months): “As a result of the above factors, Operating Profit was JPY 406.7 billion (JPY +153.2 billion and +60.4% AER, +45.0% CER).”
  • Net profit attributable to owners (six months): “Net Profit for the Period attributable to owners of the Company was JPY 305.6 billion (JPY +193.2 billion and +171.8% AER, +148.9% CER).”
  • Diluted EPS (JPY, six months): “Diluted earnings per share (loss) (JPY) | 70.45 | 189.52 | (96.75)”
  • Core EPS (six months): “Core EPS was JPY 308 (JPY +29 and +10.5% AER, -1.2% CER).”
  • Net cash from operating activities (six months): “Net Cash from Operating Activities was JPY 431.9 billion (JPY -161.8 billion).”
  • Core operating profit (six months): “Core Operating Profit was JPY 710.6 billion (JPY +71.4 billion and +11.2% AER, +0.7% CER).”
  • Gastroenterology (GI): “In GI, revenue was JPY 776.8 billion (JPY +84.0 billion and +12.1% AER, +2.5% CER).”
  • Rare Diseases: “In Rare Diseases, revenue was JPY 395.7 billion (JPY +15.2 billion and +4.0% AER, -5.6% CER).”
  • Plasma-Derived Therapies (PDT): “In PDT, revenue was JPY 561.2 billion (JPY +43.7 billion and +8.5% AER, -1.5% CER).”
  • Oncology: “In Oncology, revenue was JPY 317.0 billion (JPY +29.2 billion and +10.1% AER, +0.9% CER).”
  • Vaccines: “In Vaccines, revenue was JPY 36.6 billion (JPY +5.0 billion and +15.7% AER, +7.7% CER).”
  • Neuroscience: “In Neuroscience, revenue was JPY 220.9 billion (JPY +14.8 billion and +7.2% AER, -1.6% CER).”
  • ENTYVIO: “Sales of ENTYVIO (for ulcerative colitis and Crohn’s disease) were JPY 541.7 billion (JPY +62.4 billion and +13.0% AER, +2.7% CER).”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

Key takeaways

  1. Subcutaneous ENTYVIO is extending the GI franchise

    ENTYVIO growth in the U.S. was accompanied by growth of the subcutaneous formulation, and European growth was supported by increased subcutaneous use and rising patient numbers. This shows the franchise is being sustained through formulation, not only exchange rates.

  2. Subcutaneous immunoglobulins show strong global demand

    CUVITRU and HYQVIA, both subcutaneous immunoglobulin therapies, posted double digit percentage sales growth on continued strong demand globally. Intravenous GAMMAGARD LIQUID/KIOVIG only slightly increased.

  3. New launches grow fast but remain small

    New Launches grew by 17.3% at CER yet represented only 4% of Core Revenue. Core In-line Brands were 58% of Core Revenue and grew only 0.5% at CER.

  4. Rare disease and vaccine launches keep building

    VONVENDI grew on its expanded indication enabling prophylactic use in adults, ADZYNMA grew post-launch in Europe, and QDENGA grew post-launch in Latin America. LIVTENCITY reflected strong U.S. market penetration.

  5. Pipeline spend shifts to late-stage programs

    R&D rose on late-stage programs including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928. Takeda also impaired its gamma delta T-cell platform in the prior year after deciding to discontinue cell therapy research.

Questions

What is driving growth of Takeda's ENTYVIO?

Growth of the subcutaneous formulation in the U.S., and in Europe continued patient growth supported by increased subcutaneous use. Favorable exchange rates also helped reported sales.

How are Takeda's newer products performing?

New Launches grew by 17.3% at constant exchange rates but made up only 4% of Core Revenue. Products such as LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA all grew.

Which late-stage pipeline programs is Takeda investing in?

R&D expenses rose on late-stage programs including arcotatug tavatecan (TAK-921), elritercept (TAK-226) and TAK-928.

What is the main challenge facing Takeda's established portfolio?

Core In-line Brands were broadly flat, and growth from New Launches was more than offset by declines in loss of exclusivity-impacted and mature products. Excluding currency effects, Core Revenue slightly declined.

What is happening with demand for Takeda's plasma-derived therapies?

Subcutaneous immunoglobulins CUVITRU and HYQVIA saw double digit sales growth on strong global demand. Albumin sales rose on exchange rates but fell in the U.S.

Documents

From Takeda investor relations

SEC filing

Call recording

Listen to the official replay ↗